Cargando…

Impact of pre‐existing interstitial lung abnormal shadow on lung injury development and severity in patients of non‐small cell lung cancer treated with osimertinib

BACKGROUND: First‐generation epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) sometimes causes lung injury, thereby affecting survival. Although pre‐existing interstitial lung abnormal shadow (pre‐ILS) increases the risk of lung injury by EGFR‐TKIs, its impact on osimertinib, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shibaki, Ryota, Ozawa, Yuichi, Noguchi, Susumu, Murakami, Yusuke, Takase, Eri, Azuma, Yuichiro, Maebeya, Masaru, Sugimoto, Takeya, Hayata, Atsushi, Hayakawa, Takahiro, Tamaki, Shinya, Nakanishi, Masanori, Teraoka, Shunsuke, Akamatsu, Hiroaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582680/ https://www.ncbi.nlm.nih.gov/pubmed/35434933 http://dx.doi.org/10.1002/cam4.4750

Ejemplares similares

Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non‐Small Cell Lung Cancer
por: Akamatsu, Hiroaki, et al.
Publicado: (2019)

CD24, not CD47, negatively impacts upon response to PD‐1/L1 inhibitors in non–small‐cell lung cancer with PD‐L1 tumor proportion score < 50
por: Ozawa, Yuichi, et al.
Publicado: (2020)

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
por: Miura, Satoru, et al.
Publicado: (2023)

Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system
por: Ikeda, Mio, et al.
Publicado: (2020)

Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab
por: Ikeda, Mio, et al.
Publicado: (2021)

Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer
por: Ozawa, Yuichi, et al.
Publicado: (2020)

Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial
por: Akamatsu, Hiroaki, et al.
Publicado: (2021)

Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L)
por: Sakai, Kazuko, et al.
Publicado: (2020)

Comparison of Systemic Inflammatory Response Syndrome and quick Sequential Organ Failure Assessment scores in predicting bacteremia in the emergency department
por: Furuta, Katsuyuki, et al.
Publicado: (2021)

Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report
por: Sato, Yozo, et al.
Publicado: (2021)

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017)

Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease
por: Kiriu, Tatsunori, et al.
Publicado: (2017)

AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer
por: Murakami, Yuichi, et al.
Publicado: (2022)

Lung Cancer with Diffuse Ground-glass Shadow in Two Lungs and Respiratory Failure
por: Feng, Zhe-Min, et al.
Publicado: (2016)

Osimertinib: Pneumonitis and interstitial lung disease: case report
Publicado: (2022)

Lung Adenocarcinoma Exhibiting A Butterfly Shadow Pattern
por: Ota, Hiroki, et al.
Publicado: (2021)

Lung Cancer Screening
por: Hayata, Yoshihiro
Publicado: (1996)

Osimertinib making a breakthrough in lung cancer targeted therapy
por: Zhang, Haijun
Publicado: (2016)

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
por: Lee, Jiyun, et al.
Publicado: (2022)

Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
por: Mamesaya, Nobuaki, et al.
Publicado: (2017)

Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma: A case report
por: Inagaki, Yuji, et al.
Publicado: (2020)

A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study)
por: Shibaki, Ryota, et al.
Publicado: (2021)

A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
por: Igawa, Satoshi, et al.
Publicado: (2021)

Development of an automated size-based filtration system for isolation of circulating tumor cells in lung cancer patients
por: Yagi, Satomi, et al.
Publicado: (2017)

Malignant pleural effusion as a predictor of the efficacy of anti‐PD‐1 antibody in patients with non‐small cell lung cancer
por: Shibaki, Ryota, et al.
Publicado: (2019)

Osimertinib‐induced severe interstitial lung disease: A case report
por: Fan, Mengdi, et al.
Publicado: (2019)

Zebrafish Xenograft Model of Human Lung Cancer for Evaluating Osimertinib Resistance
por: Li, Xin-ying, et al.
Publicado: (2019)

Analysis of the clinical effect of osimertinib on 90 cases with advanced lung adenocarcinoma
por: Gao, Zhiqiang, et al.
Publicado: (2020)

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
por: Murano, Chihiro, et al.
Publicado: (2019)

Successful Treatment of EGFR-Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib
por: Batra, Ullas, et al.
Publicado: (2020)

The Association of Annexin A1 and Chemosensitivity to Osimertinib in Lung Cancer Cells
por: Chuang, Min-Chun, et al.
Publicado: (2021)

Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2019)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

Risk factors for acute exacerbation in lung cancer complicated by interstitial lung disease with slight reticular shadows
por: Takahara, Yutaka, et al.
Publicado: (2021)

Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with anti‐PD‐1 antibody
por: Murakami, Shuji, et al.
Publicado: (2020)

Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance
por: Araki, Taisuke, et al.
Publicado: (2023)

Successful retreatment with osimertinib after osimertinib-induced acute pulmonary embolism in a patient with lung adenocarcinoma: A case report
por: Shiroyama, Takayuki, et al.
Publicado: (2016)

Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows
por: Cassone, Giulia, et al.
Publicado: (2020)

Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial
por: Akamatsu, Hiroaki, et al.
Publicado: (2018)

Real‐world safety of nivolumab in patients with non‐small‐cell lung cancer in Japan: Postmarketing surveillance
por: Yamamoto, Nobuyuki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9cve86a7205lmkh0iv5oloeihl